Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Feel Good Friday: Nailing A Perfect Short Sale On Vermillion, Inc. (VRML)
May 11, 2008 01:10 AM
- Another Turnaround Tuesday?
Jan 08, 2008 10:37 AM
- US Biotech, Pharma Stocks Climb; Forest, Cypress Soar
May 23, 2007 10:58 AM
- US Biotech, Pharma Stocks Climb; Forest, Cypress Soar
May 23, 2007 10:58 AM
- Summary Of Company Studies From ASCO Conference
Jun 05, 2006 04:05 PM
- Summary Of Company Studies From ASCO Conference
Jun 05, 2006 04:05 PM
- Vion Updates Conference Call Information
Nov 04, 2008 04:31 PM
- Vion Reports 2008 Third Quarter and Nine-Month Results
Nov 03, 2008 04:30 PM
- Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Sep 22, 2008 08:01 AM
- Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
Aug 19, 2008 08:02 AM
- Vion Pharmaceuticals is Delisted from Nasdaq Stock Market
Aug 14, 2008 04:31 PM
- Vion Reports 2008 Second Quarter and Six-Month Results
Aug 04, 2008 05:01 PM
- Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Jun 13, 2008 03:30 AM
- Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Jun 02, 2008 03:06 PM
- BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
Jun 02, 2008 09:20 AM
- Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Jun 02, 2008 07:31 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
VION
|
Compare to S&P
|
| YTD |
-95.46 %
|
-92.57 %
|
| 4 Weeks |
-35.90 %
|
-30.71 %
|
| 12 Weeks |
-54.54 %
|
-36.99 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 13.21 %
|
|
EPS Growth in Last Year: 29.23 %
|
|
Sales Growth in Last Quarter: -38.46 %
|
|
Sales Growth in Last Quarter: 33.33 %
|
|
|
